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Abstract
Technological advances have increased the availability of genomic data in research and the clinic. If, over time,
interpretation of the signiﬁcance of the data changes, or new information becomes available, the question arises as to whether
recontacting the patient and/or family is indicated. The Public and Professional Policy Committee of the European Society of
Human Genetics (ESHG), together with research groups from the UK and the Netherlands, developed recommendations on
recontacting which, after public consultation, have been endorsed by ESHG Board. In clinical genetics, recontacting for
updating patients with new, clinically signiﬁcant information related to their diagnosis or previous genetic testing may be
justiﬁable and, where possible, desirable. Consensus about the type of information that should trigger recontacting converges
around its clinical and personal utility. The organization of recontacting procedures and policies in current health care
systems is challenging. It should be sustainable, commensurate with previously obtained consent, and a shared responsibility
between healthcare providers, laboratories, patients, and other stakeholders. Optimal use of the limited clinical resources
currently available is needed. Allocation of dedicated resources for recontacting should be considered. Finally, there is a
need for more evidence, including economic and utility of information for people, to inform which strategies provide the
most cost-effective use of healthcare resources for recontacting.
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Introduction
Setting the scene
Advances in genomic technologies have led to a reduction
in both the cost and speed of genome sequencing, gen-
erating unprecedented amounts of data. Genomic data may
provide information about predisposition to, and/or diag-
nosis and treatment of, many health conditions, contributing
to improved preventative therapies or surveillance regi-
mens, as well as targeting treatments to sub-groups of
patients [1]. Amalgamation of genomic data from different
populations, acquired via health care or research purposes,
and their correlation with phenotypic data further adds to
understanding the genome by analyzing data on frequency
and pathogenicity of variants, better grouping of pheno-
types, and information on the natural history of various
conditions.
A positive outcome of this increase in data collection is
the generation of more knowledge about the effect or
pathogenicity of genomic variants previously classiﬁed as
‘variants of uncertain signiﬁcance’ (VUSs; ‘variant of
unknown signiﬁcance’ and ‘variant of uncertain sig-
niﬁcance’ in this document are used as synonymous) [2],
and potentially to revising their ﬁrst interpretation. How-
ever, it also raises many questions about whether, and how,
to store and use this genomic data in the future. For
example, if a patient has had many genes sequenced, or has
had their whole exome or genome sequenced, should the
genomic data (raw or interpreted) be stored and referred to
in the future, as new information about variant-trait asso-
ciations is discovered? And if so, who would or should have
the responsibility to re-evaluate the genomic data? Who,
therefore, should ‘recontact’ the patient and family if there
are new implications of clinical importance? Should this be
the patient’s clinical care team or the clinical genetics ser-
vice (who may have had no contact with the patient)?
Should the genetic diagnostics laboratory initiate this pro-
cess, in the case of updates of previous genetic reports?
What role do patients play? Would exome or genome
reinterpretation, and (potentially) recontacting, be con-
sidered for all patients or would prioritization be necessary,
e.g., for those who did not receive a molecular diagnosis
when the original sequencing was performed? Would
information on variants related to the initial clinical problem
be prioritized? What would the logistics of the process of
recontacting look like, and what are the resource implica-
tions? Examples of recontacting scenarios are given in
Box 1.
The ESHG recommendations on whole-genome
sequencing emphasize the need for more professional gui-
dance on recontact practices [3]. It is also important to
highlight that the question of when to recontact is further
complicated by the complexity, and often the uncertainty, of
genomic information [4], meaning that recontact triggers
can be difﬁcult to deﬁne [5]. Furthermore, what constitutes
sufﬁcient evidence of pathogenicity/effect, or the lack
thereof, to justify the need to trigger recontact? [1]. As more
evidence is gathered, some uncertainty is likely to resolve
over time, which will bring the issue of recontacting into
focus. These issues become even more problematic [6] as
genetic testing, including whole exome and whole genome
sequencing, is increasingly used in mainstream medical
practice, e.g., cardiology or oncology [7]. At the core of
these questions is the tension between recognising that
appropriate recontacting could be crucial to maximizing the
beneﬁts of new genomic technologies, by improving med-
ical and/or psychosocial care for patients and/or their family
members, and identifying the resources that will enable
these beneﬁts to be realized while also minimizing potential
harm.
Box 1 Examples of scenarios for recontacting and the questions
raised
CLINICAL GENETIC HEALTH CARE SCENARIO
A child with developmental delay was referred to clinical genetics
in 2004 as the older sister was pregnant and expressed concern
regarding recurrence risk in the family. Unfortunately, no clinical
diagnosis was made. A variant in an X-linked gene was detected,
but its signiﬁcance was uncertain. The sister delivered two healthy
daughters. A decade later the signiﬁcance of the variant is
modiﬁed: it is now considered a pathogenic variant. How should
this information reach the family? Should the lab contact the
clinical geneticist? Should the clinical geneticist recontact the
family? Should the lab send a new report to the family? Should the
lab send the report to the primary HCP caring for this child?
RESEARCH SCENARIO
A child with intellectual disability was referred for clinical genetics
consultation in 2005. Unfortunately, no diagnosis was made. The
parents agreed that the information on the phenotype and the DNA
could be used for scientiﬁc research but the consent form did not
address the issue of recontacting. Ten years later exome
sequencing became available as a diagnostic tool. In a research
project on intellectual disability the child’s DNA was reanalysed
and a likely diagnosis found which might change the medical
treatment of this child. Should the parents be recontacted to inform
them of the research ﬁndings? If so, who should initiate the
recontact—the researcher or clinician in charge of the family?
NEW GENE DISCOVERY SCENARIO
A new disease gene is discovered, explaining the cause of a
complex congenital heart defect in a group of previously
undiagnosed patients, with relevant implications for their families.
Many Clinical Genetics Centres might have seen such patients
over the years. While all clinical teams bear this new diagnosis in
mind with any new referral, what should happen to the patients
they have seen in the past who are likely to have this new
diagnosis?
Recontacting their previous patients and informing them about the
possibility of genetic testing therefore arises. To date this has
largely happened on an ad hoc basis but what can be done to make
this more equitable, considering the scarcity of resources and
infrastructure limitations?
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Guidelines and consensus
A statement by the American College of Medical Genetics
(ACMG) [8], published in 1999 (currently under revision,
personal communication), is so far the only set of guidelines
in English that speciﬁcally addresses recontacting in clinical
practice. It identiﬁed the primary care physician as the key
healthcare professional (HCP) responsible for alerting
patients about the potential need to recontact, since they
provided ongoing care and were therefore best placed to
initiate and coordinate recontact. The primary care physi-
cian was expected to ask the patient about any new devel-
opments in the family history and to alert the patient to new
potential developments that could affect their health and, if
needed, to act as gatekeeper between the patient and sec-
ondary and tertiary care services, including clinical genetics
Box 2.
Ten years after the ACMG guideline, in light of the
increased uptake of genome analysis in the healthcare set-
ting, Shirts and Parker [9], among others, recognized that
diagnostic genetics laboratories (where sequencing occurs)
may be suitably placed to know about new information that
may change the previous interpretation of a variant.
Therefore, they suggest not only that laboratories should
make an effort to update relevant HCPs accordingly, but
also that they might have a responsibility to directly inform
clients of changes in test interpretation.
Later, in 2015, EuroGentest and the European Society of
Human Genetics (ESHG) issued Guidelines for diagnostic
next-generation sequencing, which emphasize that, if rein-
terpretation of variants occurs over time, the laboratory
should share some responsibility in triggering patient
recontact [10].
The concept of multidisciplinary collaboration between
genetic diagnostics laboratories and genetic HCPs is also in
line with ACMG standards and guidelines for the inter-
pretation of sequence variants. Clinical laboratories are
encouraged to establish collaborations with clinicians to
help improve genotype–phenotype relationships, and to
resolve differences in the interpretation of variants between
different laboratories [2]. Taken together, these statements
identify three important stakeholders in the process of
recontacting: HCPs (genetic HCPs and other mainstream
specialties, including primary care physicians); patients/
families; and scientists from genetics diagnostics
laboratories.
The paucity of guidelines reﬂects the variegated reg-
ulatory landscape and a lack of professional consensus
around recontacting in clinical practice [6, 11]. Importantly,
the latter includes uncertainty about whether recontacting
constitutes a duty or responsibility, and if so with whom this
would lie, and what criteria should be applied to the newly
established information in order to trigger the recontacting
process. Indeed, currently, genetic services are struggling
with these questions about duties or responsibilities, and
how these might be executed [6]. Unsurprisingly, a survey
of regulation and practices of genetic counselling in 38
European countries found that recontacting was not covered
well either in national law or applied practice guidelines
[12]. In ethical terms, genetic HCPs increasingly feel a
moral duty to recontact, even in the absence of a legal duty
to do so. Whether or not legal issues and practical issues
(resources permitting) allow for recontact may differ among
countries [12]. For instance, in Norway a very restrictive
data protection regulation is in place, so that recontacting
patients is not allowed and new contacts can only be
engendered through a new referral or if the patients them-
selves contact the service.
Towards ESHG recommendations
As indicated, there is currently a lack of consensus on many
issues related to recontacting in clinical practice, but a
growing recognition that these issues merit discussion as a
matter of priority if genomic approaches to health care are
to be realized to their potential, both clinically cost-
effectively. Attaining a professional consensus on recon-
tacting is desirable. In this paper, we provide a background
to the debate about recontacting in clinical (genetics)
practice, as well as Recommendations on Recontacting. A
group of authors involved in recent research projects on
recontacting in Europe [11, 13–17] (AML, AJC, DC, IMvL,
LJ, NH, PDT, SDh, SDo, SEK, TFHK), together with the
Public and Professional Policy Committee (PPPC) of the
ESHG, elaborated a draft background document integrated
with recommendations. These were available online on the
ESHG website for membership consultation from 28 March
Box 2 Deﬁnitions
Recontact: Establish a new contact—initiated by either former
patient or clinician – with former patients, seen in the past,
discharged from care, and no longer in an ongoing relationship
with the speciﬁc healthcare professional involved.
Follow-up: A new appointment, face-to-face or virtual, with a
current patient enrolled in ongoing care at the same Clinic/Practice.
Re-testing: Conducting a new genetic test on a patient’s sample
with an updated or a new technique with the aim to obtain new
genetic data.
Re-analysis: Using a patient’s existing raw data, that has been
sequenced in the past, in order to analyze all genes currently
proven to be associated with the patient’s condition (including
genes that were not analyzed previously, as a connection with the
patient’s condition was not known at the time).
Re-interpretation: Re-evaluation of genetic variants that have been
analyzed and interpreted in the past, in the light of new available
information. This can lead to reclassiﬁcation and possibly followed
by the provision of an updated and modiﬁed report of the
signiﬁcance of the data in question.
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to 30 April 2018, and the members as well as some experts
were invited by email to comment. All comments were
considered and adaptations made when appropriate. The
ﬁnal, amended draft has been endorsed by the Board of the
ESHG on the 15th June 2018.
For the background, we considered: (i) deﬁnitions and
conceptual clariﬁcation of recontacting in clinical practice;
(ii) current knowledge and evidence on the issue of recon-
tacting in clinical practice, particularly focused on European
countries; (iii) the available ethical and legal opinions and
guidance. We focused on recontacting in a clinical, diag-
nostic setting and have not directly addressed the issues that
arise principally in the research setting, though we recog-
nize there is overlap between the two domains.
Deﬁnitions and conceptual clariﬁcation
‘Follow up’ versus ‘recontact’
An important distinction is that between the notion of
‘recontact’ and that of ‘follow-up’. A systematic review
conducted by Otten et al. [6] deﬁnes the duty to recontact as
the ethical and/or legal obligation to recontact former
patients in light of new genetic ﬁndings. The term ‘former
patients’ allows recontacting to be distinguished from the
situation where a current patient receives routine follow-up
care. Recontacting then implies updating patients seen in
the past, and discharged from care, who are no longer in an
ongoing relationship with HCPs, but whose clinical infor-
mation and genetic data are still accessible to them.
Accordingly, recontacting involves identifying and then re-
establishing contact with former patients who could beneﬁt
from new information related to their health condition.
While this distinction between the follow-up of current
patients and the recontact of former patients is helpful, too
much focus on the semantic distinction around these terms
might lead us to miss the core of the issue. The difﬁculty
associated with this overly formal approach is the lack of
consistency as to whether a patient is (considered) dis-
charged, with variation between specialties, and between
different geographical areas even within a single country.
There are many drivers for these decisions, such as the
funding model for genetic health services in a region or
state and other political, legal, economic, historical or
practical factors [13]. Some models of health care delivery
may result in organisational barriers that could hinder the
process of recontacting, such that an action that would be
‘recontacting’ in one genetics service might be regarded as
‘routine clinical follow-up’ in another, and would therefore
fall out with the systematic review’s deﬁnition of recon-
tacting. Furthermore, most healthcare services are ﬁnan-
cially stretched and experience intense pressure to work
within limited resources which must be distributed in cost-
effective ways. In this context, recontacting ‘former’
patients and long-term follow-up both compete with new
patient referrals, which are prioritized in many healthcare
systems.
Although this argument is largely focused on clinical/
medical services, it should be restated that Genetic
Laboratories can also be directly involved in recontacting,
both directly and indirectly (through HCPs).
Duty/responsibility
The terms ‘duty’ and ‘responsibility’ to recontact are often
used interchangeably in the literature. The word ‘duty’ has
gained traction in the recontacting literature from North
American papers focusing on legal aspects [6], and con-
ceptualized recontacting as an extension of the legal duty of
care [18]. These papers tended to adopt the approach of
‘defensive’ medicine. They focused on the potential
medico-legal consequences of HCPs failing to recontact
when attempted recontact would be the expected standard
of care [19]. Thus, the aim is to limit any potential legal
liability, even in the absence of ‘an active physician-patient
relationship’ [20]. For clarity, in this paper, we wish to
distinguish between a ‘legal duty’, and a ‘professional/
ethical responsibility’. We use professional responsibility to
connote a moral or professional obligation to ensure that a
particular task is adequately performed. Contrastingly, we
use the term ‘legal duty’ in relation to a legal duty of care in
negligence, which is different in its focus and content. Such
professional responsibilities and legal duties may coexist or
may overlap [15]. However, it is important to avoid con-
ﬂating professional responsibilities and legal duties, and to
be clear about the distinction between the two.
As we will illustrate in the ‘Guiding legal and ethical
aspects’ section below, current recontacting practices are
insufﬁciently coherent and uniform to establish a legal duty
to recontact. However, practice could change in the future
and professional consensus about the importance of recon-
tacting may lead to the establishment of a legal duty. The
absence of clear legal duties to recontact leads, as a con-
sequence, to an uncertainty in terms of who is legally
responsible for what. In the absence of legal stipulations,
codes of conduct and common practice are reviewed in
cases of potential litigation. Therefore, we consider the term
‘responsibility’ more appropriate at present, and more
responsive to future changes in ethical, normative, and legal
approaches to recontacting. It is also more suitable to con-
sider a ‘collectivised’ responsibility that can include
patients, their relatives and HCPs, and potentially other
stakeholders who may also play a role in updating HCPs
about a reinterpretation of a variant of uncertain signiﬁcance
[9]. Thus, we will use the term ‘responsibility’ henceforth.
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Overview of current knowledge and
evidence on recontacting
While there is still limited empirical evidence describing
issues surrounding recontacting, the few studies conducted
in Europe provide important information. Below we present
data regarding views and experiences on recontacting from
different stakeholders.
Systematic review
We have found only one peer reviewed systematic review
of the literature on recontacting in clinical genetics [6].
This review highlights the trend to consider recontacting
as ethically desirable from the perspective of efforts to
promote effective healthcare for all, although it may be
neither fulﬁlled in practice nor logistically feasible. This
trend still continues in more recent literature [15]. The
main barriers identiﬁed by the review are lack of HCP
time and resources, and the most common proposals to
overcome these practical barriers revolve around the idea
of HCPs, patients and laboratories sharing some respon-
sibility for recontacting [6]. Furthermore, the authors note
that ethical/legal/psychosocial reasons for and against
recontacting vary in the literature. For example, new
genomic information is seen as having signiﬁcant impli-
cations for patients and family members concerning their
health, reproductive decisions, lifestyle choices, employ-
ment, and psychosocial wellbeing. However, recontacting
may also affect patients negatively, potentially causing
anxiety and concerns over health and economic activity,
and being perceived as an intrusion into privacy [6].
Accordingly, the review brings into focus that recontact-
ing is consistently seen as more compelling for relevant
and clinically valid information than for information that
is less certain or less practically useful. The authors
observe that a general responsibility to recontact in clin-
ical genetics is currently not applicable and conclude that
a useful way to advance the debate is to clarify in what
situations recontacting can be regarded as an appropriate
standard of care rather than considering a more general
responsibility to recontact [6]. While this is reasonable, it
remains to be determined what constitutes the key factors
deﬁning any one ‘situation’, as well as, from the proce-
dural perspective, how to facilitate recontacting in the face
of professional and operational constraints. The term
‘appropriate standard of care’ may also imply legal
responsibilities as well as ethical duties.
Patients’ views
The published literature describing patients’ views on
recontacting is limited.
Carrieri et al. [14] analyzed the views of patients affected
by various genetic conditions in the UK. Those interviewed
tended to consider recontacting as desirable and, as pre-
viously reported in patient-centered research about the
general attributes of genetic services [21], a sign of good
quality care. However, patients appeared to have mixed
expectations and views about the ‘signiﬁcance’ or type of
new information they would like to receive [14]. This is in
line with literature on how patients perceive the clinical
validity and personal utility of genetic testing in the clinical,
research and commercial arenas [22, 23]. An important
ﬁnding from the UK study [14] was the potentially complex
psychosocial impact on patients and family members of
receiving new information, irrespective of whether this
information is linked to an improvement of health out-
comes. Even patients who had been recontacted and had
found it to be beneﬁcial admitted that the actual experience
of the recontact triggered complex psychological responses.
Patients recognized the need to coordinate recontacting with
timely access to clinical services, so that they can be offered
the opportunity to discuss the new information and its
implications with HCPs [14]. These considerations con-
tribute to research that highlights the potentially negative
psychosocial consequences of being recontacted [24, 25].
Moreover these considerations corroborate research that
showed how patients are supportive of results being given
by qualiﬁed HCPs and, in particular, by genetic counsellors
[26].
A questionnaire study from the Netherlands [27] exam-
ined perspectives on recontacting of parents of children
affected by intellectual disability. All these children were
previously examined by karyotyping and sequencing of
speciﬁc single genes without a speciﬁc diagnosis being
reached. As the availability of high-resolution SNP array
and trio exome sequencing made re-evaluation possible,
parents were contacted either by telephone or letter. Most
interviewed parents had positive opinions on recontacting,
though it might have evoked emotional responses requiring
deeper enquiry. Interestingly, about 36% of the patients
contacted by telephone made a new appointment for re-
evaluation, compared with only 4% of those approached by
letter. The telephone call gave parents the opportunity to
make an appointment directly, and also to ask many ques-
tions. Of note, almost 90% of the parents deemed the patient
should not be responsible for initiating recontacting and
mainly identiﬁed the clinical geneticist as the HCP who
should take responsibility [27].
Also in the Netherlands, Halbersma and colleagues
(personal communication) investigated patient perceptions
of current recontacting practices by semi-structured in-depth
interviews. The speciﬁc circumstance was a variant reclas-
siﬁcation in over 150 families investigated for a hereditary
cause of cardiomyopathy. Most reclassiﬁcations involved a
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variant currently considered to be less likely to be patho-
genic, in other words a reclassiﬁcation from likely patho-
genic to VUS. At the time over 40 patients had been
informed by letter explaining the variant reclassiﬁcation and
its consequences, and inviting them to contact the genetics
department if they had questions, which surprisingly none
of them did. Subsequent in-depth interviews with ten of
these patients showed that they had appreciated being
recontacted about the reclassiﬁcation and felt that they
needed no additional information. However, it was apparent
that their understanding of the information was sometimes
inaccurate (e.g. incorrect conclusions about transmissability
and implications for their relatives).
A recent American questionnaire study [28] examined
the feasibility, efﬁcacy and patient opinions on recontacting
by letter in a setting of adults previously affected by
endocrine tumours (medullary thyroid carcinoma, phaeo-
chromocytoma, paraganglioma). These patients were likely
affected by a hereditary syndrome, but genetic testing at the
time of initial assessment could not be completed, if per-
formed at all. Almost all the patients who completed the
survey deemed it appropriate for them to be sent informa-
tion on new developments which could have implications
for their or their family’s health, even though a minority
were distressed by this. Despite the alleged positive recep-
tion, only a third further discussed the possibility of genetic
testing with their doctor, and less than 10% actually
underwent testing. The authors consequently questioned the
effectiveness of this approach and proposed that research be
pursued on more effective methods with improved patient
satisfaction.
Overall, the studies currently available demonstrate that
patients value being recontacted by HCPs, although this can
represent for them a psychologically complex and stressful
experience and may not lead to (medically) appropriate
actions.
Views from HCPs and clinical genetics laboratory
professionals
One survey study administered to 105 genetics centres in
Europe [13] (including 20 UK centres [11]) suggests that
most centres in Europe have recontacted patients in the light
of new signiﬁcant information, but only a minority reported
recontacting as a routine activity [13]. The survey answers
revealed a multiplicity of understandings of the term
‘recontacting’; some respondents appeared to consider
routine follow-up programmes or even the post-test result
counselling to be part of recontacting [13]. This observation
was mirrored in empirical research with patients and HCPs
conducted in the UK [14].
The most common barriers for recontacting mentioned
by European HCPs included lack of resources (time,
reimbursement, staff, infrastructure), concerns about
potential negative psychological consequences of recon-
tacting for the patients, existing policies or laws that prevent
HCPs from recontacting, and difﬁculties in locating patients
after their last contact. Variation between European genetics
centres in terms of procedures related to recontacting may
be due to the highly variable evolution of the disciplines of
medical genetics and genetic counselling across different
European countries [13].
In line with the European survey results, Carrieri et al.
[11] reported that recontacting occurs in the UK mostly in
light of new information that HCPs consider to be clinically
relevant for the patient. However, there are no standardized
practices. HCPs attributed the ad hoc nature of current
recontacting practices to a lack of resources (time, stafﬁng
and infrastructure). This means that there is no systematic
way to ensure that all patients seen in a clinic who may
beneﬁt from new information are identiﬁed and recontacted
[11]. This links recontacting to the broader issue of the
equitability of current healthcare service provision [15].
Professionals’ and patients’ associations can also sub-
stantially contribute in updating HCPs and patients with
new relevant information on speciﬁc conditions and help
facilitate the recontact.
In the Dutch study on recontacting of parents of children
affected by intellectual disability the researchers found
recontacting feasible but very time-consuming, and a mas-
sive additional responsibility for clinical geneticists [27].
Overall, the genetic professionals deem recontacting
patients over time valuable for the patient, but burdensome
and very difﬁcult to systematically realize in practice, even
impossible in some scenarios due to legal and infrastructure
barriers.
Professional responsibility for recontacting
The EuroGentest (EG) and the ESHG Guidelines for diag-
nostic next-generation sequencing, published in 2015 [10],
state that Genetic laboratories are ‘not expected to re-
analyze old data systematically and report novel ﬁndings’,
however, ‘if at a particular moment, it is decided—by the
lab or by the community of experts in the disease—to
change a variant from one class to another, the laboratory is
responsible for reanalyzing the available data, re-issuing a
report on the basis of the novel evidence, and also re-
contacting referring clinicians for the patients that are pos-
sibly affected by the new status of the variant’ [10] (p. 5).
Although some responsibility for recontacting is acknowl-
edged in principle to fall to the genetic laboratories, the
practicability remains elusive.
Vears et al. [29] propose points to consider to labora-
tories offering diagnostic genome analysis. In line with the
EG-ESHG guidelines [10], they also support the view that
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laboratories do not have an obligation to routinely reanalyse
data but rather in response to a speciﬁc request initiated by
the patient or their clinician. However, if the information on
reclassiﬁcation of a given variant becomes available to the
laboratory, then it would be considered good clinical
practice for those laboratories to identify patients carrying
that variant from their database and issue a new report to the
original referring clinician [29]. It is also worth noting that,
in the wider context, laboratories might have different rules
in reporting, such that at present there is inconsistency, not
only concerning whether or not a VUS is reported, but also
sometimes on variant classiﬁcation, even using the same
guidelines for interpretation.
El Mecky, Johansson et al. (personal communication)
undertook an online focus group of all clinical genetics
laboratories in the Netherlands to discuss their current
practice and views about future practice regarding the
reclassiﬁcation of variants, as well as which reclassiﬁcations
are communicated from laboratory to clinician. Preliminary
results indicate differing views on which reclassiﬁcations
merit recontacting from laboratory to clinician. Further-
more, no systematic approaches exist for laboratories to
actively reinterpret variants (i.e. periodically reviewing new
evidence on genetic variants in the laboratory’s database,
unprompted by patient or clinician), but some participants
desired to implement such procedures.
The UK study [11, 15] reports a lack of agreement
between genetic HCPs and clinical scientists in the
laboratory about whose role it should be to monitor the
changing interpretations of variants so that appropriate
recontacting can be triggered.
The lack of a professional consensus was cited by
respondents as another important cause of the ad hoc nature
of recontacting. Some HCPs expressed the concern that they
could be legally liable either if they recontact patients or if
they fail to do so [15]. Interestingly, Carrieri et al. [11] also
found a potential tension between a patient’s right not to
know and HCPs’ responsibility or duty to recontact [30,
31]. For example, many survey respondents answered that
they would, in a hypothetical situation, recontact patients
and family members in light of new clinically relevant
information, even if the patients had indicated they would
not want them to do so. This perspective is, to some extent,
related to the ESHG recommendations on the use of whole-
genome sequencing in healthcare, in particular that:
“Patients’ claims to a right not to know do not automatically
over-ride professional responsibilities when the patient’s
own health or that of his or her close relatives is at stake”
[3] (p. 583). Given the hypothetical nature of a previously
expressed preference not to be recontacted, and the potential
responsibility of HCPs to the patient’s relatives, HCPs may
consider whether the relevance of the new information to be
conveyed to the patient and/or their family would justify a
re-exploration of the earlier decision of the patient, or even
a disclosure in the case of serious and actionable health
risks, particularly if not previously anticipated. Moreover,
the background document on consent and conﬁdentiality of
the UK Joint Committee on Genomics in Medicine [32]
suggests that consideration should be given to viewing
consent as a process, rather than as a one-off event. This
view could indicate that HCPs should consider the decisions
made during the initial consent process to be dynamic over
time.
A suggestion made by both patients and HCPs inter-
viewed in the UK was that recontacting could be a ‘joint
venture’ between patients and HCPs; that is, that patients
and HCPs could share some responsibility for recontacting
[16, 17]. This argument was mainly based on two factors:
(i) the issue of the lack of resources to implement recon-
tacting sustainably within resource-constrained healthcare
service, and (ii) discourses about patients’ responsibility to
manage their own health (see Section 'Guiding legal and
ethical aspects'). However, placing an onus of responsibility
on the patient or family has the potential to introduce
inequity and to maintain or exacerbate disparities in health
and health care. Those who are more burdened by disease
personally or in their family, who are unemployed or living
in poverty, who are less articulate or less educated, who
have less internet competence or access, or who have any
cognitive impairment, may be less likely to rise to the
challenge of initiating recontact when it might be appro-
priate. This may result in HCPs addressing more demands
of people with elevated social advantages but whose health
needs may be less, which—as described in Tudor Hart’s
Inverse Care Law—may reinforce pre-existing inequities
[33]. It should be an aim to avoid this outcome.
Guiding legal and ethical aspects
Legal aspects
There are two main areas of law which govern recontacting
in Europe: (i) negligence/duty of care, and (ii) data
protection. In addition, the regulatory frameworks of indi-
vidual nation states which govern medical practice and
genetic testing may have relevance to aspects of
recontacting. However, these will vary from state to state
and a comprehensive review is outside the scope of this
article.
Negligence
In Europe, the law of negligence differs across nations, and
the common law approach (taken in England & Wales, and
Ireland) is different to that in civil law jurisdictions.
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Common law approach HCPs owe a duty to take reason-
able care of their patients. To succeed in a negligence action
(tort), a person must show that there has been a breach of
this duty of care which has caused harm [34, 35]. The
standard of care is judged by reference to a responsible
body of professional opinion, or in other words, the stan-
dard practice of the profession or specialty, as long as that
practice could not be rejected as incapable of standing up to
rational analysis (Bolam v Friener Hospital Management
Committee [1957] 2 All ER 118; Bolitho v Hackney Health
Authority [1998] AC 232; Montgomery v Lanarkshire
Health Authority [2015] AC 1430). Currently, recontacting
occurs in the clinical genetics context largely in an ad hoc
manner. In the absence of consistent practice, or any pro-
fessional consensus about a professional responsibility to
recontact, a legal duty of care is unlikely to arise at present.
However, the nature of common law is such that, should
practice change in the future, there may be sufﬁcient weight
of practice and professional consensus about the importance
of recontacting to establish a legal duty to recontact.
Civil law approach According to the civil law and the tort
law, three core facts should be demonstrated to prove the
professionals’ duty: a fault, a damage, and a causal link
between the two. The fault should consist, in health law, in
having failed to provide a standard of care [36]. This
standard of care is evaluated by the judge according to the
medical knowledge at the date of the damage and can either
consist of the commission or omission of an act. Among the
faults that jurisprudence considers as impinging on patients’
rights and autonomy (such as information, consent) are
faults which can be compensated. The damage should
usually be proven by the patient and can include loss of an
opportunity for intervention regarding his medical condi-
tion. The patient should also characterize the link between
the fault and the damage. These rules are implemented
differently in the different European countries, which can
adopt speciﬁc provisions regarding medical liability and
command discretion in interpreting the scope of the fault
and the burden of proof.
Data protection
As with all areas of medical practice, data protection law
regulates key aspects of the processing of information about
patients. It provides a framework to allow patients to apply
for access to their personal data. This will allow proactive
patients to recontact their HCPs to seek access to their
personal data (although this does not include a requirement
for reanalysis or updating of their medical information).
However, the data protection framework does not provide a
means for patients to compel HCPs to recontact them
without application on their part. Most aspects of HCPs
recontacting patients are likely to be non-controversial in
many countries, and permitted by data protection law,
providing that there is appropriate provision of information
and consent to the use of data. Article 9 of the General Data
Protection Regulation [37] governs the processing of
genetic and medical information, which is a special cate-
gory of personal data. Such data may be processed where a
person has given explicit consent or under the scientiﬁc
research exemption or for substantial public interest. In the
absence of such consent, including if a patient has refused
consent to be recontacted, the HCP aiming to conclude a
diagnosis for the patient and their family beneﬁt, could rely
on either Art 9(g) (substantial public interest) or (h) (med-
ical diagnosis) to make their conduct compliant with data
protection law; however, the result should be kept by the
physician if the individual has claimed his right not to
know.
Ethical aspects
HCPs, as revealed through research studies and professional
debates [15, 28], have highlighted an urgent need for gui-
dance about the circumstances in which recontacting should
be considered a good standard of care, and about lines of
responsibility [13]. Such guidance would reduce the current
lack of clarity that HCPs are experiencing in relation to the
clinical and medico-legal aspects of recontacting. Ideally, it
should also lead to a more consistent and equitable
healthcare service provision around recontacting.
Beneﬁcence, non-maleﬁcence, autonomy and justice
With respect to how recontacting could beneﬁt patients,
new information conveyed when a patient is recontacted
might entail clinical or personal utility [22, 38, 39], and
potentially improve the health of the patient or family; for
instance, through directing them to appropriate management
strategies. However, it is not always certain that the overall
outcome, including psychosocial aspects, will be sig-
niﬁcantly improved. In a study from the Netherlands, for
instance [27], 17% of parents recontacted for their child’s
intellectual disability mentioned positive emotions, such as
hopeful and relief, and negative emotions, such as grief,
anger, fear and frustration. Indeed, recontacting might
represent a source of anxiety and stress for the patient and
family members, as it might be perceived as an intrusion of
privacy and breach of their right not to know. The new
contact might elicit memories of an emotionally difﬁcult
episode of their life, which had meanwhile been ‘archived’
or put aside, and which they might not wish to re-
experience. The new information provided might also have
an impact on practical, ﬁnancial and legal aspects of their
situation, for example their eligibility for health and life
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insurance, adoption applications, and so on. The decision on
whether or not to recontact a patient at a certain moment
would require careful weighing of all the above-mentioned
factors and, inevitably, with ﬂexibility. Decisions will
inevitably be made on a case-by-case basis.
On the other hand, and mirroring the ongoing debate
around the issue of disclosure of unsolicited ﬁndings (UFs;
ﬁndings beyond the initial clinical question) to participants/
patients in clinical, research and commercial arenas [40–42]
—for certain types of results (i.e. high penetrance, severity
of phenotype)—there seems to be a progressive opening to
consider the ‘Justiﬁed hard paternalism’ framework [43].
According to this framework the ‘duty to warn’ is inter-
preted as a ‘duty to rescue’, which is felt to be obligatory
beneﬁcence. Under this framework, the cardinal genetic
counselling tenets of patient autonomy and the right-not-to-
know (central in the ‘respect’ pillar of the clinical ethics
framework) [44, 45] are currently being challenged. Con-
sent procedures might also shift accordingly from an ‘opt
in’ to an ‘opt out’ framework, as well as items discussing
the option of data sharing, for instance with other family
members, are shifting from ‘choice’ to ‘information’. In this
context, it will be essential to carefully consider, in dialogue
with all stakeholders, and with consideration of legal and
ethical standards to protect patients’ autonomy and right not
to know, whether a patient’s one-off choices about hypo-
thetical future scenarios (including on recontacting) would
be considered as strictly binding for all types of
information.
In this respect it is worth mentioning a pilot project run
by the Clinical Genetics working group of the Italian
National Society of Human Genetics (SIGU) in 2009, which
resulted in the document ‘Continuità Assistenziale in
Genetica Clinica: il ricontatto’ (‘Continuity of care: recon-
tacting’ [46], document in Italian only). The document
suggested that, whatever the policy of the service on
recontacting, it should have been clearly explained to the
patient. In a case where active recontacting would have
been a potential option, written consent should be obtained
from the patient, in order to be compliant with privacy
policies. A model consent form was also suggested. A
subsequent survey found that, despite a general agreement
regarding recontacting being in principle good practice,
only a net minority of centres declared to have adopted a
bespoke consent. The reasons provided included a written
consent being unnecessary and fear of litigation in case
recontacting would not have been executed (personal
communication).
Regardless of the model of consent that is eventually
adopted, in order for patients to be able to make an
informed decision about testing it is important that a dis-
cussion about recontact takes place during the consent
process. Indeed, a study by Ayuso et al. [47] proposed that
recontact should be included as one of the core elements on
consent forms provided to patients undergoing diagnostic
genomic sequencing. Another, more recent study undertook
a systematic search for consent forms available online and
in English that were in use for high-throughput diagnostic
next generation sequencing [48]. Fifty-eight consent forms
were analysed to assess their policies for recontacting
patients, and the mechanisms for doing so. Only 23/58
forms mentioned some form of recontact for clinical pur-
poses. There was considerable variation regarding who
would initiate recontact if new information was identiﬁed:
forms most commonly stated that the laboratory would
recontact the clinician (8 forms), or the patient (8 forms), or
recommended that the patient should recontact the clinician
to check if their results have changed (6 forms). Only in
four cases patients were asked to give separate consent for
clinical purposes. It is important that the roles and respon-
sibilities of the laboratory, clinician, and patient are clearly
deﬁned to ensure all parties are aware of their part in the
process. The consent process provides the best opportunity
for such clariﬁcation as a speciﬁc conversation about
recontacting can be initiated between clinician and patient
when seeking to cover all points of information. From a
legal perspective, discussing consent for future recontacting
may be key to ensuring alignment with data protection
requirements and protection of persons’ rights.
From the perspective of social justice the effort needed
for recontacting has to be proportionate and sustainable.
Though ideally all patients who may beneﬁt from new
information are identiﬁed and recontacted, there is no
guarantee that each clinic would have the resources to meet
these ideals, and HCPs are allowed to recontact so inequity
might result.
Discussion
In clinical genetics, recontacting patients over time is
sometimes performed in Europe, with HCPs reporting that
it mostly occurs when new, clinically relevant information
or new techniques become available [13]. However, there
are no standardized criteria, practices or systems in place
for recontacting to occur [13]. Importantly, there is a lack
of economic evidence about the relative costs and con-
sequences of strategies to recontact patients, either in
general or for individuals with speciﬁc diseases. Recon-
tacting thus raises the broader issue of equity in current
healthcare service provision, in that there is no systematic
way to ensure that all patients who may beneﬁt from new
information are identiﬁed and recontacted, and also that
ﬁnite healthcare resources may force decision makers to
prioritize elsewhere. Even if a systematic approach was
proposed, there is no guarantee that each clinic would
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have the resources to meet these ideals, so inequity would
result.
The few existing empirical studies [11, 13, 15, 27, 28]
found that HCPs deem recontact theoretically possible, but
there is signiﬁcant concern among HCPs that they may be
held legally liable whether they do, or do not, recontact
patients [11, 15]. Both HCPs and patients express concerns
about a lack of clarity over roles and responsibilities [14,
15]. This lack of clarity is further complicated by the fact
that genetic and genomic testing is increasingly offered by
specialties that do not necessarily have an ongoing
relationship with a patient [49, 50], and non-genetic spe-
cialists may not be equipped to communicate information
on reclassiﬁed variants. HCPs see the need for professional
guidance about whether, and in what circumstances,
to recontact, and whose responsibility this should be
[13, 15].
Furthermore, both HCPs and patients have expressed
concerns about the feasibility of routinely recontacting
within the current resource constraints of healthcare
systems [13, 15, 17, 27]. An ‘opportunity cost’ argument
has been developed in favour of timely recontacting
being an effective use of healthcare resources, con-
sidering the potential preventative value of correct
information, its psychosocial beneﬁts and ultimately
improving health outcomes. Moreover, when dealing
with inherited conditions, the ‘cost-effectiveness’ ana-
lyses should also include the repercussions on family
members, and not only the patient in isolation. To be
convincing, however, this premise requires the support
of evidence from the ﬁeld of health economics. An
additional consideration that favours recontacting, from
a clinical perspective, is that its implementation may
provide opportunities to gather more information about
the natural history of genetic conditions and their impact
on patients and families over time, contributing to
interpretative knowledge.
In summary, the evidence currently available [13, 14]
suggests that recontacting patients is viewed as desirable by
the relevant stakeholders, notwithstanding its complexities
and objective hurdles. At present, there is no economic
evidence to support or to oppose to its introduction.
The development of professional guidelines and appro-
priate tools and procedures to achieve this implementation
would be welcomed.
A precondition to making recontacting feasible is the
simpliﬁcation of the process as much as possible, and this
can only be achieved with suitable informatics tools,
appropriately set up.
Electronic medical records, genetics laboratory data-
bases, and patients’ registries, all represent powerful
tools to identify, monitor and reach patients who might
beneﬁt.
The genetics laboratories are the ﬁrst repositories of the
variants which might be reinterpreted over time, and as such
the ideal point of departure for triggering recontact through
the referring clinicians. Centralization of laboratory facil-
ities and their collaboration with data sharing tools and
curated databases might simplify this process. Profes-
sionals’ and patients’ associations can also substantially
contribute in updating HCPs and patients with new, relevant
information on speciﬁc conditions, and facilitating the
recontact.
While identifying different stakeholders in sharing
responsibility to recontact, including patients, genetic
and non-genetic HCPs, and lab specialists, such shared
responsibility should be seen as a pragmatic way forward
until best practices have been identiﬁed. Meanwhile
we should be aware of the risk that expecting others to
assume responsibility may result in failure to take any
action.
If a routine follow-up of the patient is in place with
another specialty, their involvement should be considered,
as that specialist will have insight into the present situation
of the patient and the process may be more streamlined.
As genetic and genomic testing becomes progressively
more integrated in mainstream medicine, the identiﬁcation
of the HCP who should take the initiative in re-evaluating
the case of the patient and/or recontacting them may
become even more intricate. The implementation of
multidisciplinary teams (MDTs) involved in the care of
rare and/or complex cases has been introduced in some
settings and can support good practice. However, this may
require a long time to be consistently and systematically
implemented and might not apply to all possible
situations.
Whether or not MDT meetings take place, it is in any
case desirable for collaboration and coordination to be
established among all the HCPs involved in the care of a
patient. This would create opportunities to evaluate indivi-
dual cases in a collegial way, assist in the integration of the
resources and information available, and arrive at the most
reasonable decision on how to manage individual cases,
including the practical delivery of care.
Considering recontact practices over time may offer an
opportunity for HCPs, policy makers and other stakeholders
to focus on long-term strategies (as opposed to the prevalent
‘short-termism’) for the delivery of an efﬁcient and sus-
tainable health service, which would proactively contribute
in sustaining the positive circle of the implementation of e-
health records.
An open dialogue will be important to promote public
engagement, enhance recognition of the need for data sharing,
and build conﬁdence in the mechanisms for enabling that
process. If such demonstrably trustworthy systems can be built,
this will be to the great beneﬁt of patients and their families.
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Recommendations
1. If possible, recontact should take place for
ﬁndings with clinical or established personal utility,
even though currently there is no duty to do so
In clinical genetics, recontacting for updating patients with
new, meaningful information related to their diagnosis or
their previous genetic testing may be justiﬁable and, where
possible, it is desirable. The consensus about the type of
information to disclose that should trigger the recontacting
process converges around clinical and personal utility.
2. The decision to recontact should be based on the
best interests of the patient/family
The decision to recontact should be guided by the best
interests of the patient/family and on the basis of previous
agreements with the entitled person(s). The anticipated
beneﬁts of recontacting should outweigh the risks to the
patient/family. Any tensions between the best interest or
wishes of a patient versus those of the family should be
carefully considered. It will be important to consider whe-
ther the new information for professionals to convey is
linked to the original clinical question or not, and to take
account of the previous, hypothetical choices of the patient
regarding being informed of possible collateral or unsoli-
cited ﬁndings.
3. Recontacting should be sustainable for the health
care system and its workforce
The effort needed for recontacting has to be proportionate
and sustainable, from the perspective of social justice. The
beneﬁts for patients and their families should be balanced
with the impact that the recontacting activities may have on
HCPs’ work and the service as a whole in order to ensure
the just offer of clinical care. This should not prevent HCPs
and services from offering excellent, equitable, trusted
clinical care in the future.
4. The allocation of dedicated resources for
activities on recontacting should be considered
Sustainable and equitable recontacting cannot be
achieved without suitable informatics tools, appropriately
set up. Ideally these should be integrated into the Elec-
tronic Clinical Records and the databases of diagnostic
genetics laboratories. Implementation of patients’ regis-
tries also represents a powerful tool. Resources should be
allocated for research on recontacting procedures.
Research is needed to further understand recontacting
activities and how they could best be organised, including
research on HCPs’ activities and development of infor-
matics tools.
5. Recontacting should strive to be equitable for
patients from all socioeconomic backgrounds and
contexts
When implementing recontact in practice, it will be
important to deﬁne strategies to ensure we are addressing
the patients’ needs on the basis of clinical priority while
tackling inequalities in healthcare access and individual
resources. People who are more burdened by disease or
poverty, less articulate or educated, cognitively impaired,
with less IT access or fewer skills, merit special con-
sideration. Particular attention should be devoted to patients
whose test was conducted while they were children, whose
legal status might have changed, and who might not have
been fully informed about their previous contacts with a
clinical genetics service and their outcomes.
6. There is a need for professional consensus about
what constitutes good practice regarding consent
for recontacting
It will be important that HCPs who are offering genetic
testing/counselling address the practical and ethical issues
of recontacting. HCPs should clearly state what may hap-
pen, assess and record each patient’s views, and agree on
the way forward, involving patients when possible. A wider
debate on the evolution of consent and conﬁdentiality issues
in clinical genetics will be needed.
7. Recontacting should be a shared responsibility
with patients
Where patients relocate or change their mind in respect of
being recontacted, it is important for the genetics service to
be kept informed. Placing additional responsibility on
patients to initiate recontacting might be seen as a pragmatic
solution to the current lack of resources and infrastructure
but risks distracting services from their most important tasks
and reinforcing inequities in health care. Any patient-led
recontacting requires an effective partnership between
patient and genetic services, in which the patient is offered
education on why, how and when s(he) might consider
establishing a new contact with a genetics centre.
8. Recontacting should be a shared responsibility
with the genetic laboratories
Genetics laboratories are the natural repositories of the
genetic variants identiﬁed in patients, which might be
reclassiﬁed over time. As such, they might represent the
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ideal point of departure for triggering the recontacting
process, by alerting the referring clinician about the new
information. Laboratory scientists might therefore share
responsibilities in recontacting. Multi-specialty collabora-
tions between HCPs and clinical genetics laboratories
appear to be one of the most effective ways to implement
recontacting in clinical practice in a smooth and equitable
way. In case the recontacting might involve a direct contact
between the laboratory and the patient, where this is
allowed or required by the local healthcare system, appro-
priate information on the patient’s recorded consent on the
matter should be obtained.
9. Data sharing should be promoted
The centralization of laboratory facilities, progressive
adoption of data sharing tools and of curated databases
might support and simplify both the re-interpretation of
VUSs and the implementation of the recontacting process.
An open dialogue to promote patient and public engage-
ment and enhance recognition of the importance of data
sharing, explaining the clinical utility of whole exome/
genome sequencing approaches, as well as their complex-
ities, will be instrumental in developing these systems for
the beneﬁt of the patients and their families.
10. Other stakeholders should also share
responsibility for recontacting
Non-genetic HCPs, Professional Networks (as for instance
European Reference Networks for Rare Disorders) and
Patients’ Associations, represent crucial stakeholders who
should also be involved in the recontacting debate. Net-
works of professionals and patients can also contribute to,
and facilitate, the recontacting process by updating both
HCPs and patients with new relevant information.
In health care, if routine follow-up of a patient is in place
with non-genetic specialists, their involvement should not
only be considered but possibly represent the main route for
conveying new or updated information to the patient.
11. Do the best you can with limited resources
At present, all healthcare systems throughout the EU are
working with ﬁxed and limited budgets and often
struggling to maintain even basic services. In this sce-
nario, and without the appropriate resources, it is difﬁ-
cult to expect Genetics Services to recontact patients in a
consistent and systematic way, if at all. We propose that
this activity will be included within the workload of
Genetics HCPs but for that it must be appropriately
resourced. There is a need for economic evidence to
inform decisions about which strategies enable the most
cost-effective use of healthcare resources to recontact
patients.
12. Each country should deﬁne its own
organizational policy on the recontact process
As European countries have different healthcare systems
and legal frameworks it will be essential to identify in each
nation the relevant stakeholders, the protocol options, and
the resources to be allocated before any systematic recon-
tacting can be operational. While this process might require
a considerable amount of time, we urge that a dialogue be
started among stakeholders at the level of each country to
promote a harmonisation of the procedures at the national
level, even if it cannot yet be achieved at the European
level. Regional and national experiences can inform Eur-
opean initiatives for harmonisation. Resources should be
allocated for pilot programmes implementing recontacting
procedures.
13. More research is needed to inform responsible
recontacting processes
Additional research on how stakeholders, including patients
and families, experience recontact, and how it impacts the
economics of healthcare systems, should be supported in
order to help inform the development of a responsible re-
contacting process and develop tools to support dynamic
consent procedures.
Closure
While genetic services seem to be the central focus now,
genomic testing is becoming increasingly integrated within
mainstream medicine, which will contribute to the devel-
opment of a new ‘genomic medicine’ vision, even if it may
not come to pass in practice exactly as envisaged. In
addition, experience from evolving frameworks and pro-
cesses, such as screening programmes and the return of
results from research using biobanks, will be informative.
We expect to revise this document in the light of such
ongoing experiences in the coming years.
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